ArticleJournal of managed care & specialty pharmacy2021

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.

Vivian Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.